Q-omics provides the consensus-scored TRAPPC6A profile across patient tissues and cancer cell-line models. TRAPPC6A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRAPPC6A is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TRAPPC6A protein abundance shows 26,746 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, THCA, and PDAC as cancer lineages where TRAPPC6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAPPC6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAPPC6A survival associations across molecular data types. TRAPPC6A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAPPC6A RNA expression–survival associations across cancer types. High TRAPPC6A expression shows unfavorable associations in ACC, UCS and BRCA, but favorable associations in DLBC, LUSC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRAPPC6A RNA expression.
This table summarizes TRAPPC6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRAPPC6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAPPC6A shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in COAD, LIHC and BRCA. The THCA box plot shows higher TRAPPC6A RNA expression in normal versus tumor tissue (log2 FC = −1.217, t-test p < 0.001).
This table shows molecular features associated with TRAPPC6A in patient tissues and cancer cell lines. In patient samples, TRAPPC6A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAPPC6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
